Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S.

Cell. 2019 Aug 22;178(5):1189-1204.e23. doi: 10.1016/j.cell.2019.07.044.

PMID:
31442407
2.

Granulomatous lobular mastitis-Another paradigm shift in treatment.

Brownson KE, Bertoni DM, Lannin DR, Cohen PJ, Pronovost MT.

Breast J. 2019 Jul;25(4):790-791. doi: 10.1111/tbj.13338. Epub 2019 May 20. No abstract available.

PMID:
31111604
3.

Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?

Heller DR, Chiu AS, Farrell K, Killelea BK, Lannin DR.

Cancers (Basel). 2019 Apr 8;11(4). pii: E500. doi: 10.3390/cancers11040500.

4.

Treatment Intensity for Mammographically Detected Tumors: An Alternative Viewpoint.

Lannin DR.

Ann Surg Oncol. 2018 Sep;25(9):2502-2505. doi: 10.1245/s10434-018-6641-0. Epub 2018 Jul 9. No abstract available.

PMID:
29987608
5.

Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected?

Chagpar AB, Tsangaris TN, Lannin DR.

J Am Coll Surg. 2018 Jul;227(1):13-21. doi: 10.1016/j.jamcollsurg.2018.03.003. Epub 2018 Mar 8.

PMID:
29524664
6.

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.

Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB.

J Oncol Pract. 2017 Dec;13(12):e1012-e1020. doi: 10.1200/JOP.2017.022731. Epub 2017 Oct 19.

PMID:
29048991
7.

Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?"

Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR.

Am J Surg. 2017 Dec;214(6):1089-1090. doi: 10.1016/j.amjsurg.2017.09.025. Epub 2017 Sep 30. No abstract available.

PMID:
28987415
8.

Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?

Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR.

Am J Surg. 2017 Dec;214(6):1082-1088. doi: 10.1016/j.amjsurg.2017.07.036. Epub 2017 Sep 18.

PMID:
28939252
9.

Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer.

Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR.

Ann Surg Oncol. 2017 Oct;24(10):3073-3081. doi: 10.1245/s10434-017-5936-x. Epub 2017 Aug 1.

PMID:
28766195
10.

Regional variation in breast cancer surgery: Results from the National Cancer Database (NCDB).

Chiu AS, Thomas P, Killelea BK, Horowitz N, Chagpar AB, Lannin DR.

Am J Surg. 2017 Nov;214(5):907-913. doi: 10.1016/j.amjsurg.2017.07.008. Epub 2017 Jul 18.

PMID:
28736057
11.

Are Small Breast Cancers Good because They Are Small or Small because They Are Good?

Lannin DR, Wang S.

N Engl J Med. 2017 Jun 8;376(23):2286-91. doi: 10.1056/NEJMsr1613680. No abstract available.

12.

Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience.

Berrocal J, Saperstein L, Grube B, Horowitz NR, Chagpar AB, Killelea BK, Lannin DR.

Surg Res Pract. 2017;2017:5924802. doi: 10.1155/2017/5924802. Epub 2017 Apr 13.

13.

Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.

Killelea BK, Chagpar AB, Horowitz NR, Lannin DR.

Am J Surg. 2017 Feb;213(2):426-432. doi: 10.1016/j.amjsurg.2016.05.018. Epub 2016 Jul 21.

PMID:
27769548
14.

Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database.

Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR.

Medicine (Baltimore). 2016 Aug;95(35):e4614. doi: 10.1097/MD.0000000000004614.

15.

Racial Differences in Utilization of Breast Conservation Surgery: Results from the National Cancer Data Base (NCDB).

Thomas P, Killelea BK, Horowitz N, Chagpar AB, Lannin DR.

Ann Surg Oncol. 2016 Oct;23(10):3272-83. doi: 10.1245/s10434-016-5475-x. Epub 2016 Aug 8.

PMID:
27503494
16.

Breast cancer biology varies by method of detection and may contribute to overdiagnosis.

Hayse B, Hooley RJ, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR.

Surgery. 2016 Aug;160(2):454-62. doi: 10.1016/j.surg.2016.03.031. Epub 2016 May 27.

PMID:
27241117
17.

Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial.

Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP.

Ann Surg. 2017 Jan;265(1):39-44. doi: 10.1097/SLA.0000000000001799.

18.

Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.

Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR.

J Clin Oncol. 2015 Dec 20;33(36):4267-76. doi: 10.1200/JCO.2015.63.7801. Epub 2015 Nov 23.

PMID:
26598753
19.

Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.

Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN.

Int J Cancer. 2016 Feb 1;138(3):747-57. doi: 10.1002/ijc.29808. Epub 2015 Aug 31.

20.

Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? A prospective cohort study.

Chagpar AB, Butler M, Killelea BK, Horowitz NR, Stavris K, Lannin DR.

Am J Surg. 2015 Nov;210(5):886-90. doi: 10.1016/j.amjsurg.2015.05.018. Epub 2015 Jul 18.

PMID:
26255230
21.

Supplemental ultrasonography screening for women with dense breasts.

Hayse B, Lannin DR.

Ann Intern Med. 2015 Jun 2;162(11):801-2. doi: 10.7326/L15-5061-2. No abstract available.

PMID:
26030641
22.

A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer.

Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR.

N Engl J Med. 2015 Aug 6;373(6):503-10. doi: 10.1056/NEJMoa1504473. Epub 2015 May 30.

23.

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.

Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB.

Cancer. 2015 Aug 1;121(15):2544-52. doi: 10.1002/cncr.29348. Epub 2015 Apr 22.

24.

Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.

Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR.

J Am Coll Surg. 2015 Jun;220(6):1063-9. doi: 10.1016/j.jamcollsurg.2015.02.011. Epub 2015 Feb 26.

PMID:
25868410
25.

Characteristics of Multifocal and Multicentric Breast Cancers.

Kanumuri P, Hayse B, Killelea BK, Chagpar AB, Horowitz NR, Lannin DR.

Ann Surg Oncol. 2015 Aug;22(8):2475-82. doi: 10.1245/s10434-015-4430-6. Epub 2015 Mar 25.

PMID:
25805233
26.

The left sided predominance of breast cancer is decreasing.

Onibokun O, Killelea BK, Chagpar AB, Horowitz NR, Lannin DR.

Breast J. 2015 Mar-Apr;21(2):213-5. doi: 10.1111/tbj.12385. Epub 2015 Jan 13. No abstract available.

PMID:
25582054
27.

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL.

Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.

28.

Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.

Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V.

Clin Cancer Res. 2014 Dec 1;20(23):5995-6005. doi: 10.1158/1078-0432.CCR-14-1622. Epub 2014 Sep 25.

29.

Risk and benefits of screening mammography.

Lannin DR.

JAMA. 2014 Aug 13;312(6):649. doi: 10.1001/jama.2014.7658. No abstract available.

PMID:
25117136
30.

Impact of financial burden of cancer on survivors' quality of life.

Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB.

J Oncol Pract. 2014 Sep;10(5):332-8. doi: 10.1200/JOP.2013.001322. Epub 2014 May 27.

PMID:
24865220
31.

Smoking and breast cancer recurrence after breast conservation therapy.

Bishop JD, Killelea BK, Chagpar AB, Horowitz NR, Lannin DR.

Int J Breast Cancer. 2014;2014:327081. doi: 10.1155/2014/327081. Epub 2014 Feb 17.

32.

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.

Brown JR, DiGiovanna MP, Killelea B, Lannin DR, Rimm DL.

Lab Invest. 2014 Jan;94(1):98-106. doi: 10.1038/labinvest.2013.128. Epub 2013 Nov 4.

33.

The number of lymph nodes dissected in breast cancer patients influences the accuracy of prognosis.

Wiznia LE, Lannin DR, Evans SB, Hofstatter EW, Horowitz NR, Killelea BK, Tsangaris TN, Chagpar AB.

Ann Surg Oncol. 2014 Feb;21(2):389-94. doi: 10.1245/s10434-013-3308-8. Epub 2013 Oct 17.

PMID:
24132625
34.

Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast.

Sue GR, Lannin DR, Au AF, Narayan D, Chagpar AB.

Am J Surg. 2013 Nov;206(5):682-5. doi: 10.1016/j.amjsurg.2013.07.001. Epub 2013 Sep 4.

PMID:
24011572
35.

Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance?

Killelea BK, Chagpar AB, Bishop J, Horowitz NR, Christy C, Tsangaris T, Raghu M, Lannin DR.

Ann Surg Oncol. 2013 Oct;20(10):3247-53. doi: 10.1245/s10434-013-3155-7. Epub 2013 Aug 22.

PMID:
23975299
36.

Is the use of preoperative breast MRI predictive of mastectomy?

Killelea BK, Grube BJ, Rishi M, Philpotts L, Tran EJ, Lannin DR.

World J Surg Oncol. 2013 Jul 12;11:154. doi: 10.1186/1477-7819-11-154.

37.

Predictors of microinvasion and its prognostic role in ductal carcinoma in situ.

Sue GR, Lannin DR, Killelea B, Chagpar AB.

Am J Surg. 2013 Oct;206(4):478-81. doi: 10.1016/j.amjsurg.2013.01.039. Epub 2013 Jun 19.

PMID:
23791403
38.

Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?

Bai HX, Motwani SB, Higgins SA, Haffty BG, Wilson LD, Lannin DR, Evans SB, Moran MS.

Int J Clin Oncol. 2014;19(3):460-6. doi: 10.1007/s10147-013-0575-0. Epub 2013 Jun 19.

PMID:
23780727
39.

Does time to definitive treatment matter in patients with ductal carcinoma in situ?

Sue GR, Lannin DR, Killelea B, Tsangaris T, Chagpar AB.

Am Surg. 2013 Jun;79(6):561-5.

PMID:
23711263
40.

Effect of screening mammography on breast cancer incidence.

Lannin DR.

N Engl J Med. 2013 Feb 14;368(7):678. doi: 10.1056/NEJMc1215494. No abstract available.

PMID:
23406037
41.

Factors associated with breast MRI use: a population-based analysis.

Killelea BK, Lannin DR, Horvath LJ, Horowitz NR, Chagpar AB.

Ann Surg Oncol. 2013 Jun;20(6):1798-805. doi: 10.1245/s10434-012-2758-8. Epub 2012 Dec 1.

PMID:
23208129
42.
43.

Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen.

Bordeaux JM, Cheng H, Welsh AW, Haffty BG, Lannin DR, Wu X, Su N, Ma XJ, Luo Y, Rimm DL.

PLoS One. 2012;7(5):e36559. doi: 10.1371/journal.pone.0036559. Epub 2012 May 11.

44.

Realistic appraisal of the benefits of mammography.

Lannin DR.

Arch Intern Med. 2012 Apr 23;172(8):672-3. doi: 10.1001/archinternmed.2012.355. No abstract available.

PMID:
22529241
45.

Cytoplasmic estrogen receptor in breast cancer.

Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL.

Clin Cancer Res. 2012 Jan 1;18(1):118-26. doi: 10.1158/1078-0432.CCR-11-1236. Epub 2011 Oct 6.

46.

What do breast surgeons do?

Schwartz JC, Rishi M, Christy CJ, Grube BJ, Lannin DR.

Am J Surg. 2009 Oct;198(4):544-6. doi: 10.1016/j.amjsurg.2009.06.001.

PMID:
19800465
47.

Re: Precancerous lesions of the breast.

Tavassoli FA, Lannin DR.

Nat Clin Pract Oncol. 2009 Mar;6(3):E1. doi: 10.1038/ncponc1344. No abstract available.

PMID:
19247307
48.

Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter.

Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR.

Ann Surg Oncol. 2009 Mar;16(3):697-702. doi: 10.1245/s10434-008-0268-5. Epub 2009 Jan 9.

PMID:
19132447
49.

Breast sentinel lymph node dissection before preoperative chemotherapy.

Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR.

Arch Surg. 2008 Jul;143(7):692-9; discussion 699-700. doi: 10.1001/archsurg.143.7.692.

PMID:
18645113

Supplemental Content

Loading ...
Support Center